Adam invests at the intersection of biology, healthcare, technology and data. He is interested in the digitization of healthcare; genomics and coding biology; the microbiome; neuroscience and brain-computer interfaces; next-gen bio-imaging; regenerative medicine; and other areas of applied hard sciences. Adam was most recently a General Partner at Lux Capital where he founded and incubated a number of companies including Cajal Neuroscience, VNV Bio and Kallyope where he was the founding CEO. Fascinated with the potential of digitization in life sciences and the broader healthcare ecosystem, Adam has invested in companies that span the realms of virtual clinical trials and real world evidence platforms to single particle tracking microscopy drug discovery companies. Prior to his career in venture, Adam was a Postdoctoral Fellow of Neuroscience at Weill Cornell Medical College, researching regenerative stem cell medicine in association with brain disorders such as schizophrenia and Alzheimer’s disease. Originally from Australia, Adam has dual undergraduate degrees in Business and Science and a PhD from the Australian Stem Cell Centre, where he was a Premier Scholar. He has been published in numerous peer-reviewed, scientific journals. Adam loves to travel the world with his better half Mez, and has been known to wake up at all hours of the night to tune into Aussie Rules football matches.